MarketPulse

Foundayo

13 articles
BenzingaBenzinga··Mohd Haider

Eli Lilly's VERVE-102 Gene Therapy Cuts LDL Cholesterol 62%, Draws VC Praise

Eli Lilly reports VERVE-102 gene therapy reduced LDL cholesterol up to 62% in Phase 1b trials with no serious adverse events, earning FDA Fast Track designation.
LLYbiotechgene therapy
The Motley FoolThe Motley Fool··Adria Cimino

Eli Lilly's Oral Pill Gamble: Foundayo Threatens Zepbound, Expands Empire

Eli Lilly launches Foundayo oral GLP-1 pill, risking Zepbound cannibalization while potentially capturing new weight loss drug users amid $12B+ quarterly demand.
PFELLYNVOVKTXGLP-1 drugsZepbound
BenzingaBenzinga··Vandana Singh

Eli Lilly's Weight-Loss Portfolio Expansion Signals Sustained Demand Despite Price Pressures

Eli Lilly reports positive maintenance data for Foundayo and lower-dose Zepbound, with Mounjaro revenue surging 125% to $8.7B and Zepbound reaching $4.1B despite pricing headwinds.
LLYNVOrevenue growthclinical trial results
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Eli Lilly's Growth Trajectory Remains Compelling for Late Investors

Eli Lilly's 56% revenue growth and 156% EPS surge in Q1 2026, driven by GLP-1 dominance and oral formulation expansion, signal continuing upside potential for investors.
LLYearnings growthpharmaceutical growth
The Motley FoolThe Motley Fool··Adria Cimino

Eli Lilly's Weight Loss Arsenal Accelerates: GLP-1 Portfolio Surges Past $12.7B

Eli Lilly's weight loss drugs deliver explosive growth with Mounjaro up 125% and Zepbound up 80%. New oral drug Foundayo already serves 20,000 patients.
PFELLYNVOVKTXmarket sharepharmaceutical growth
Investing.comInvesting.com··Nathan Reiff

Lilly's Double-Beat Widens GLP-1 Gap as Foundayo Pill Transforms Market

Eli Lilly beats Q1 earnings, raises $2B guidance, and wins FDA approval for Foundayo, the first unrestricted oral GLP-1, widening gap over Novo Nordisk.
LLYNVOFDA approvalweight loss medications
BenzingaBenzinga··Vandana Singh

Eli Lilly Crushes Expectations, Raises 2026 Outlook on GLP-1 Dominance

Eli Lilly beat Q1 earnings expectations and raised full-year guidance, driven by blockbuster demand for weight-loss drugs Mounjaro and Zepbound.
LLYearningsacquisitions
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Morgan Stanley Sees 52% Upside for Eli Lilly as Weight-Loss Drugs Reshape Revenue

Morgan Stanley analyst targets $1,327 for Eli Lilly, citing $45B weight-loss drug sales potential by 2030, implying 52% upside from current $870 levels.
LLYCVSNVOweight loss drugsZepbound
The Motley FoolThe Motley Fool··David Jagielski, Cpa

Eli Lilly's GLP-1 Pill Approval Sets Stage for $1 Trillion Valuation Return

Eli Lilly received FDA approval for Foundayo weight-loss pill in April 2026. With 40%+ growth and premium valuation, stock needs only 20% gain to hit $1 trillion market cap.
LLYFDA approvalmarket valuation
BenzingaBenzinga··Vandana Singh

Eli Lilly's Oral Weight Loss Drug Clears Cardiovascular Safety Hurdle

Eli Lilly's oral weight loss drug Foundayo met cardiovascular safety goals in Phase 3 trials, showing 57% lower mortality risk versus insulin. FDA filing planned for Q2 2026.
LLYFDA approvalweight-loss drug
BenzingaBenzinga··Sweta Killa

Lilly's Mounjaro Loses Ground in India as Generic GLP-1s Surge

Eli Lilly's Mounjaro loses market share in India to cheaper GLP-1 generics; sales fell 16% in March. FDA approves Lilly's oral GLP-1 Foundayo.
LLYNVOGLP-1 drugsweight loss drugs
The Motley FoolThe Motley Fool··Justin Pope

Eli Lilly's FDA-Approved Obesity Pill Could Upend Novo Nordisk's Market Dominance

Eli Lilly's new GLP-1 pill Foundayo launches April 6 with fewer restrictions than competitors. Pipeline drug retatrutide shows superior weight loss, threatening Novo Nordisk's obesity market leadership.
LLYNVOFDA approvalGLP-1 drugs
The Motley FoolThe Motley Fool··Eric Volkman

Eli Lilly Surges on FDA Approval of Foundayo, Challenging Novo Nordisk's Weight-Loss Dominance

Eli Lilly stock surged 4% after FDA approval of Foundayo, its oral weight-loss pill priced at $149/month, competing with Novo Nordisk's Wegovy.
LLYNVOFDA approvalstock performance